PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Active transforming growth factor-β2 in the aqueous humor of posterior polymorphous corneal dystrophy patients.

Abstract Posterior polymorphous corneal dystrophy (PPCD) is characterized by abnormal proliferation of corneal endothelial cells. It was shown that TGF-β2 present in aqueous humor (AH) could help maintaining the corneal endothelium in a G1-phase-arrest state. We wanted to determine whether the levels of this protein are changed in AH of PPCD patients.
PMID
Related Publications

Decreased active TGF-beta2 levels in the aqueous humour during immune reactions following penetrating keratoplasty.

Immunohistochemical characterization of cytokeratins in the abnormal corneal endothelium of posterior polymorphous corneal dystrophy patients.

Soluble Fas ligand and transforming growth factor beta2 in the aqueous humor of patients with endothelial immune reactions after penetrating keratoplasty.

Active transforming growth factor-beta2 is increased in the aqueous humor of keratoconus patients.

Determination of active TGF-beta2 in aqueous humor prior to and following cryopreservation.

Authors

Mayor MeshTerms
Keywords
Journal Title plos one
Publication Year Start




PMID- 28414732
OWN - NLM
STAT- MEDLINE
DA  - 20170417
DCOM- 20170425
LR  - 20170425
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 12
IP  - 4
DP  - 2017
TI  - Active transforming growth factor-beta2 in the aqueous humor of posterior
      polymorphous corneal dystrophy patients.
PG  - e0175509
LID - 10.1371/journal.pone.0175509 [doi]
AB  - PURPOSE: Posterior polymorphous corneal dystrophy (PPCD) is characterized by
      abnormal proliferation of corneal endothelial cells. It was shown that TGF-beta2 
      present in aqueous humor (AH) could help maintaining the corneal endothelium in a
      G1-phase-arrest state. We wanted to determine whether the levels of this protein 
      are changed in AH of PPCD patients. METHODS: We determined the concentrations of 
      active TGF-beta2 in the AH of 29 PPCD patients (42 samples) and 40 cadaver
      controls (44 samples) by ELISA. For data analysis the PPCD patients were divided 
      based on either the molecular genetic cause of their disease as PPCD1 (37
      samples), PPCD3 (1 sample) and PPCDx (not linked to a known PPCD loci, 4 samples)
      or on the presence (17 samples) or absence (25 samples) of secondary glaucoma or 
      on whether they had undergone penetrating keratoplasty (PK, 32 samples) or
      repeated PK (rePK, 7 samples). RESULTS: The level of active TGF-beta2 in the AH
      of all PPCD patients (mean +/- SD; 386.98 +/- 114.88 pg/ml) in comparison to the 
      control group (260.95 +/- 112.43 pg/ml) was significantly higher (P = 0.0001).
      Compared to the control group, a significantly higher level of active TGF-beta2
      was found in the PPCD1 (P = 0.0005) and PPCDx (P = 0.0022) groups. Among patients
      the levels of active TGF-beta2 were not significantly affected by gender, age,
      secondary glaucoma or by the progression of dystrophy when one or repeated PK
      were performed. CONCLUSION: The levels of active TGF-beta2 in the AH of PPCD
      patients are significantly higher than control values, and thus the increased
      levels of TGF-beta2 could be a consequence of the PPCD phenotype and can be
      considered as another feature characterizing this disease.
FAU - Stadnikova, Andrea
AU  - Stadnikova A
AUID- ORCID: http://orcid.org/0000-0002-3571-3946
AD  - Laboratory of the Biology and Pathology of the Eye, Institute of Inherited
      Metabolic Disorders, First Faculty of Medicine, Charles University and General
      University Hospital in Prague, Czech Republic.
FAU - Dudakova, Lubica
AU  - Dudakova L
AD  - Laboratory of the Biology and Pathology of the Eye, Institute of Inherited
      Metabolic Disorders, First Faculty of Medicine, Charles University and General
      University Hospital in Prague, Czech Republic.
FAU - Skalicka, Pavlina
AU  - Skalicka P
AD  - Department of Ophthalmology, First Faculty of Medicine, Charles University and
      General University Hospital in Prague, Czech Republic.
FAU - Valenta, Zdenek
AU  - Valenta Z
AD  - Department of Medical Informatics & Biostatistics, Institute of Computer Science,
      Czech Academy of Sciences, Prague, Czech Republic.
FAU - Filipec, Martin
AU  - Filipec M
AD  - European Eye Clinic Lexum, Prague, Czech Republic.
FAU - Jirsova, Katerina
AU  - Jirsova K
AD  - Laboratory of the Biology and Pathology of the Eye, Institute of Inherited
      Metabolic Disorders, First Faculty of Medicine, Charles University and General
      University Hospital in Prague, Czech Republic.
LA  - eng
PT  - Journal Article
DEP - 20170417
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Transforming Growth Factor beta2)
RN  - Corneal Dystrophy, Posterior Polymorphous, 1
RN  - Corneal Dystrophy, Posterior Polymorphous, 3
SB  - IM
MH  - Aqueous Humor/*metabolism
MH  - Cornea/*metabolism
MH  - Corneal Dystrophies, Hereditary/*metabolism
MH  - Endothelium, Corneal/metabolism
MH  - Female
MH  - Glaucoma/metabolism
MH  - Humans
MH  - Keratoplasty, Penetrating/methods
MH  - Male
MH  - Middle Aged
MH  - Transforming Growth Factor beta2/*metabolism
EDAT- 2017/04/18 06:00
MHDA- 2017/04/26 06:00
CRDT- 2017/04/18 06:00
PHST- 2016/09/14 [received]
PHST- 2017/03/27 [accepted]
AID - 10.1371/journal.pone.0175509 [doi]
AID - PONE-D-16-36915 [pii]
PST - epublish
SO  - PLoS One. 2017 Apr 17;12(4):e0175509. doi: 10.1371/journal.pone.0175509.
      eCollection 2017.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>